Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) Operating cash flow
Charles River Laboratories International, Inc.'s operating cash flow for fiscal 2025 was $737.6M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $582.1M. Over the past ten years it has ranged from $306.8M (fiscal 2015) to $760.8M (fiscal 2021); the current reading is higher than 91% of that period. Operating cash flow has risen for 3 consecutive fiscal years. Charles River Laboratories International, Inc. ranks 14th of 52 Diagnostics & Research companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $737.6M | 0.42% |
| FY2024 | $734.6M | 7.41% |
| FY2023 | $683.9M | 10.37% |
| FY2022 | $619.6M | (18.55%) |
| FY2021 | $760.8M | 39.19% |
| FY2020 | $546.6M | 13.65% |
| FY2019 | $480.9M | 9.02% |
| FY2018 | $441.1M | 38.69% |
| FY2017 | $318.1M | 0.37% |
| FY2016 | $316.9M | 3.28% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $179.7M | 337.53% |
| Mar 2026 | $41.1M | (72.15%) |
| Dec 2025 | $147.5M | (31.01%) |
| Sep 2025 | $213.8M | 4.51% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $1.9B |
| LH Labcorp Holdings Inc. compare | $1.6B |
| ICLR ICON PLC compare | $1.1B |
| MEDP Medpace Holdings, Inc. compare | $752.7M |
| QGEN QIAGEN N.V. compare | $654.5M |
| RVTY Revvity Inc. compare | $627.6M |
| CRL Charles River Laboratories International, Inc. | $582.1M |
| TWST Twist Bioscience Corporation compare | −$53.1M |
| GH Guardant Health, Inc. compare | −$185.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement